Loading…
Korean biotech developing bispecific antibodies for cancer and neurodegenerative disease, licensed to global partners including Sanofi.
Korean biotech developing bispecific antibodies for cancer and neurodegenerative disease, licensed to global partners including Sanofi.
Earns from upfront and milestone payments in licence deals rather than product sales, so income arrives in large, uneven amounts tied to partners' trial progress. The Grabody platform, which carries drugs across the blood-brain barrier, is the technology partners pay for.
Moat: narrow (IP / patents). Proprietary bispecific antibody platform validated by large global pharma licensing deals.
Headquarters: Seongnam, South Korea · Founded: 2011 · Employees: 108
Size ABL Bio (298380.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.49B, the 172nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩36,050 on 6 Nov 2026.
Performance Over six months the shares fell 73.3%, against -15.7% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 63.9% over the last twelve months (peer median +6.3%); the operating margin is -251.2% (peer median 6.6%).
Valuation It trades at 55.7× enterprise value to sales against a peer median of 7.1× (3rd most expensive of 19).
Capital Return on invested capital runs 103.3 points below its cost of capital (5.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩34.3B | ₩79.3B | ₩33.4B | ₩65.5B | ₩67.3B |
| Revenue growth | — | +138% | -49% | -3% | — |
| Gross profit | ₩2.38B | ₩45.9B | ₩11.3B | ₩41.4B | ₩45.6B |
| EBITDA | -₩82.2B | -₩36.9B | -₩57.0B | -₩27.3M | ₩3.23B |
| Net income | -₩78.6B | -₩37.8B | -₩55.5B | -₩2.65B | ₩3.21B |
| Free cash flow | -₩47.1B | -₩61.3B | -₩78.4B | -₩34.1B | ₩68.8B |
| Capital expenditure | ₩6.05B | ₩20.7B | ₩9.06B | ₩5.84B | ₩3.64B |
| Total debt | ₩55.4B | ₩55.3B | ₩43.7B | ₩43.9B | ₩41.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| ABL Bio 298380.KS | $1.49B | -73% | -64% | -251% | 55.7× | n/a |
| LigaChem Biosciences 141080.KS | $1.59B | -68% | -33% | -208% | 18.4× | n/a |
| Aimed Bio 0009K0.KS | $875M | -61% | +223% | 36% | 16.4× | 13.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 298380.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.4% | +0.1% | lowest of 21 |
| 6-month return | -73.3% | -15.7% | lowest of 21 |
| Distance from 52-week high | -86.0% | -35.8% | lowest of 21 |
| Revenue growth (TTM) | -63.9% | +6.3% | 2nd lowest of 19 |
| Operating margin | -251.2% | 6.6% | 3rd lowest of 19 |
| EV / Sales | 55.7× | 7.1× | 3rd most expensive of 19 |
| ROIC minus cost of capital | -103.3 pp | -4.7 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | 15.5× | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 1.5× | -5.8% | +1.9% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |